Takeda Pharmaceutical Company Limited
NYSETAK short interest plummets 59.5% in a week to 2.78M shares, with cost to borrow falling to 0.58% and utilization at 35%.
Short interest % of float, cost to borrow, utilization, and put/call ratio for TAK are part of the ORTEX premium tier. Sign up to read the live numbers alongside the analysis.
Snapshot as of 7 May 2026
No long-form analysis yet for TAK. Pulse alerts and the live data picture are available on ORTEX.
Open TAK on ORTEX →Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for TAK — free to start on ORTEX.
Sign up for free →Open TAK on ORTEXPulses are triggered by ORTEX's live data feeds. The full signal history, thresholds, and alerts are on ORTEX.
Live TAK data →